irritable bowel syndrome

The company said its test is the first biomarker-based diagnostic for IBD that predicts long-term disease outcome in Crohn's disease and ulcerative colitis.

The companies aim to develop microbiome diagnostic assays for colon cancer and other gastrointestinal diseases including irritable bowel syndrome.

Qualified patients will have immediate access to IQuity's MS test, with expected access later to an IBD-IBS test, and a fibromyalgia test.

The agreement, with Genetic Analysis of Oslo, involves technology to detect gut dysbiosis and investment for additional tests.

The researchers used this approach to show how non-coding variation associated with human immune dysfunction alters context-specific gene programs. 

IQuity's current tests analyze gene expression patterns detected in mRNA, but the firm is also exploring the diagnostic potential of long non-coding RNAs.

The test, which detects various bacterial species in fecal samples, is expected to be submitted to US regulators before the end of this year.

Genetic Analysis CEO Kari Stenersen said the deal is a "commercial breakthrough" for the Oslo-based company.

NEW YORK (GenomeWeb News) – The nonprofit Crohn's and Colitis Canada has awarded nearly C$800,000 (US$740,000) to fund three omics research projects that will investigate genes involved in inflammatory bowel diseases (IBD) and a possible method for treating such diseases.

Pages

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.